Home>CREON Patient Support>Treatment Tracker

Treatment Tracker

The CREON Treatment Tracker allows patients to record their daily routine and then share that information with you at their next appointment. This easy-to-use tool can help you assess how a patient’s treatment plan is going and if any adjustments may be needed.

Download the Treatment Tracker and share it with your patients.

Download Treatment
Tracker

Request patient starter kits,
product samples, and more

Contact a Rep

Determine an appropriate
per-meal dose for your patients

Use Dosing Guide

Indications and Important
Safety Information

Indications¹

CREON^® (pancrelipase) Delayed-Release Capsules is a pancrelipase which is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.

Important Safety Information

Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement in the treatment
of cystic fibrosis patients. Exercise caution when doses of CREON exceed 2,500 lipase units/kg of body weight
per meal (or greater than 10,000 lipase units/kg of body weight per day).
To avoid irritation of oral mucosa, care should be taken to ensure that CREON is not crushed, chewed, or retained in the mouth. CREON should always be taken with food.
Porcine-derived pancreatic enzyme products contain purines. Caution should be exercised when prescribing CREON to patients with gout, renal impairment, or hyperuricemia.
There is theoretical risk of viral transmission with all pancreatic enzyme products including CREON.
Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
Adverse reactions that occurred in at least 2 cystic fibrosis patients (greater than or equal to 4%) receiving CREON were vomiting, dizziness, and cough.
Adverse reactions that occurred in at least 1 chronic pancreatitis or pancreatectomy patient (greater than or equal to 4%) receiving CREON were hyperglycemia, hypoglycemia, abdominal pain, abnormal feces, flatulence, frequent bowel movements, and nasopharyngitis.
CREON is not interchangeable with any other pancrelipase product.